simplyStocks
Incyte
INCY · NASDAQBiotechnology
The economic chain
Follow the chain left → right, from inputs to end demand. Tap any company to trace its links.
Raw inputs
Equipment
Foundry
Chip design
Software
AI demand
—
Company details
Market cap
$20B
P/E ratio
20×
Div yield
0%
EPS (TTM)
$5.00
Profit margin
19%
Rev. growth
+20%
Revenue
$5.1B
Cash & investments
$3.5B
In plain English
Incyte is a Wilmington, Delaware biopharma built on one blockbuster: Jakafi (ruxolitinib), a JAK inhibitor for blood cancers and graft-versus-host disease that is ~60% of its sales. It has spent that cash diversifying — into a fast-growing skin cream (Opzelura), an oncology bag bought in (Monjuvi/tafasitamab from MorphoSys, Niktimvo with Syndax, Zynyz from MacroGenics), and a deep late-stage pipeline — while Novartis sells Jakafi as Jakavi outside the US and Eli Lilly sells the Incyte-discovered Olumiant, both paying Incyte royalties.
In simple terms
What Incyte really sells
Incyte is a Wilmington, Delaware biopharma built on one blockbuster: Jakafi (ruxolitinib), a JAK inhibitor for blood cancers and graft-versus-host disease that is ~60% of its sales. It has spent that cash diversifying — into a fast-growing skin cream (Opzelura), an oncology bag bought in (Monjuvi/tafasitamab from MorphoSys, Niktimvo with Syndax, Zynyz from MacroGenics), and a deep late-stage pipeline — while Novartis sells Jakafi as Jakavi outside the US and Eli Lilly sells the Incyte-discovered Olumiant, both paying Incyte royalties.
Tip · Click any company in the map to learn — in one sentence — what it actually does and why it matters.
Risk read
SteadierMore speculative
Why this rating?